RAD50 and cancer: Therefore, our medaka mutant demonstrated that, as shown by experimental animals with other defective MRN-ATM pathway molecules, the loss-of-function mutation of rad50 would have tumorigenic properties; however, further studies are required to elucidate the clinical significance of the RAD50 mutation in human cancers.